A New Treatment, the Same Old Barriers
When I was asked to write about a new narcolepsy medication, I wasn't too sure where to begin. Initially, I didn't think I could write about it at all.
I live in Portugal. I haven't taken this medication, I don't have access to it, and I doubt I will any time soon. Access to established treatments can already be complicated here.
Why I decided to write about this narcolepsy treatment
What changed my mind was remembering that I'm not alone in this. Unfortunately, there are still so many of us without access. As advocates, we are not only working to improve our own lives, but also the lives of others who share our struggle.
Staying awake is something many people rarely have to think about. For those of us living with narcolepsy, it is a basic privilege we cannot always take for granted.
How orexin and Orzeyful relate to narcolepsy type 1
Orexin, also called hypocretin, is a chemical messenger that helps the brain maintain wakefulness and regulate sleep. In narcolepsy type 1, the cells that produce it are largely lost, leaving the brain without enough of a signal it relies on.
Oveporexton, marketed as Orzeyful, works by activating orexin receptor 2, one of the receptors that normally responds to that messenger. This helps compensate for the missing signal and can improve wakefulness and reduce cataplexy.
It is a treatment, not a cure. But its approach offers another way to explain why staying awake is not simply a matter of deciding to "make more effort".
When narcolepsy symptoms are mistaken for choices
For me, this brings another part of living with narcolepsy into focus: how often the effects of that missing signal are interpreted as something I have chosen.
The biology of narcolepsy was understood long before this medication. Yet explaining what happens in the brain can still feel much easier than getting someone to understand what it means in an ordinary day.
Someone can hear that I have a neurological condition and still expect me to overcome its effects when something important comes along.
Missing my niece's school performance because of narcolepsy
A while ago, I wrote an article called "Does Narcolepsy Make Me Unreliable?", in which I spoke about missing my niece's school performance because I simply couldn't get out of bed that day. My body had completely failed me.
I understood why my niece and her parents were disappointed. What hurt was the suggestion that keeping my promise had been entirely within my control.
They could see that I had not arrived. They could not see what had made getting there impossible.
For me, this is where people's responses make a difference.
Even when people cannot see what narcolepsy does to us, they can choose to respect our reality.
How location shapes narcolepsy treatment access
And while the conversation about treatment moves forward, so many of us still have to live within the options available to us.
Living in different countries has taught me how much location can shape life with narcolepsy. The diagnosis alone does not tell you which treatments you can obtain, what support you can receive, or which difficulties you will have to navigate.
Now, I am looking at yet another treatment development from Portugal, not knowing when, or if, it could become a realistic option for me.
While I can't write about what this medication feels like to take, I can write about living with symptoms that are frequently mistaken for choices, and about how where I live shapes the treatment options available to me.
What it will take for narcolepsy progress to reach everyone
I want better treatments to become accessible to everyone. Access to medical treatment should not depend on where someone happens to live.
I also want people to understand that those still living with symptoms are not failing to make enough effort. Our need to be believed remains, whether a treatment is available to us or not.
What will it take for medical progress to make a difference to everyone's lives, rather than a select few?
Meanwhile… our need for support does not disappear while we wait.



Join the conversation